Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2020-11-09 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Encouraging Results Against SARS-CoV-2 Virus 3 pages 467.0KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated November 10, 2020, reporting preliminary results from an antiviral screening program evaluating a compound (RECCE 327) against SARS-CoV-2. It includes scientific data such as IC50 values and mentions ongoing and future testing stages. The text is structured as a press release with highlights, scientific results, and company background. There are no financial statements, regulatory certifications, or detailed management discussions typical of annual or interim reports. It is not a transcript, audit report, or governance document. The content focuses on research progress and is an update to the market rather than a formal financial or regulatory filing. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-11-09 English
Reinstatement to Official Quotation 1 page 409.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to official quotation of Recce Pharmaceuticals Ltd. It mentions the lifting of suspension of trading following an announcement about anti-viral testing results. The document is very short (645 characters) and does not contain any financial data, detailed report, or management discussion. It is an official notice related to trading status on the exchange, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement. It is not a full report, earnings release, or other specific filing type.
2020-11-09 English
Extension of Voluntary Suspension 1 page 257.2KB
Regulatory Filings Classification · 95% confidence The document is a letter from the company secretary of Recce Pharmaceuticals Ltd to the ASX requesting a voluntary suspension of trading of the company's securities. It references ASX Listing Rule 17.2 and states the suspension is pending the release of an announcement related to anti-viral testing results. The document is short (1059 characters) and is a formal request for trading halt, not a financial report or announcement of results. It does not contain financial data, management changes, voting results, or any other report content. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement to the exchange that does not fit other specific categories.
2020-11-08 English
Suspension from Official Quotation 2 pages 435.0KB
Regulatory Filings Classification · 100% confidence The document is a market announcement from Recce Pharmaceuticals Ltd regarding a voluntary suspension of its securities from official quotation on the ASX. It references Listing Rule 17.2 and states the suspension is pending the release of an announcement related to anti-viral testing results. The document is short (1762 characters) and is an official notice about trading suspension, not a financial report or detailed disclosure. It does not contain financial data, management discussion, or audit information. It is clearly an announcement related to regulatory compliance and trading status, fitting best under Regulatory Filings (RNS).
2020-11-04 English
Trading Halt 2 pages 477.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Recce Pharmaceuticals Ltd regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement related to anti-viral testing results. The document is short (1844 characters) and does not contain any financial data, report content, or detailed analysis. It is an announcement about a trading halt, not a financial report or detailed disclosure. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-11-02 English
Investor Presentation 29 pages 4.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Recce Pharmaceuticals Ltd, including disclaimers, company background, capital structure, major shareholders, board and management structure, and product information. It contains no financial statements or quarterly results but is structured as an investor presentation with strategic and operational information. The presence of slides, disclaimers about investment advice, and detailed company and product descriptions indicate this is an Investor Presentation (IP). The document length (15,000 characters) and content confirm it is not a brief announcement or a regulatory filing. Therefore, the classification is Investor Presentation (IP).
2020-10-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.